株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

CNS (中枢神経系) の世界市場の分析

Analyzing the Global CNS Market 2018

発行 Aruvian's R'search 商品コード 249850
出版日 ページ情報 英文 175 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.17円で換算しております。
Back to Top
CNS (中枢神経系) の世界市場の分析 Analyzing the Global CNS Market 2018
出版日: 2018年04月01日 ページ情報: 英文 175 Pages
概要

当レポートでは、世界の中枢神経系 (CNS) 市場について分析し、CNS疾患の概略や、世界のCNS市場の基本構造、世界全体の市場動向の分析、主な市場促進・抑制要因、薬剤クラス別の詳細動向、主要製品の売上高の見通し、新規薬品の開発・治験の動き、競合情勢、主要企業のプロファイルといった情報を取りまとめてお届けいたします。

エグゼクティブサマリー

CNS (中枢神経系) 疾患:概略

  • CNS (中枢神経系) とは何か?
  • CNS疾患

世界のCNS市場

  • 市場概要
  • 主なCNS製品
  • 特許満了の影響
  • CNS関連の薬剤パイプライン
  • 業界内部の研究開発 (R&D) 活動

市場への影響要因

  • 成長促進要因
  • 市場が直面している課題

各種の薬剤クラスの販売実績

  • 概要
  • 抗うつ薬
  • 抗てんかん薬
  • アルツハイマー病治療薬
  • 偏頭痛治療薬
  • 抗精神病薬
  • パーキンソン病治療薬
  • 睡眠薬・鎮静剤
  • 精神刺激薬

現在開発中/近年開発されたCNS治療薬

  • 概要
  • バピネオズマブ
  • Botox (onabotulinumtoxin-A)
  • IPX066
  • Levadex
  • LY2216684/NERI
  • MK-4305
  • Potiga/Trobalt
  • RG1678/RO4917838
  • Silenor
  • ソラネズマブ
  • Stedesa
  • TC-5214 (S-メカミルアミン)
  • テルカゲパント
  • Valdoxan/Thymanax

世界のCNS治療薬市場の将来予測

業界内部での競合関係

業界を代表する企業

  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • Pfizer

用語集

調査手法

目次

The CNS market at a global scale has been one of the largest and fastest growing markets in the pharmaceutical industry. Reimbursement terms remain favorable within the area, despite the relatively high risks associated with product development. This is largely due to significant levels of unmet medical need and the clinical specificity of many CNS drugs.

The CNS disorders market may be segmented into numerous subcategories, including Alzheimer's disease (AD), epilepsy, insomnia, major depressive disorder (MDD), Parkinson's disease (PD), migraine, schizophrenia, attention-deficit hyperactivity disorder (ADHD), bipolar disorder among others. Antipsychotics were the largest CNS drug class. Patent expirations of key brands Seroquel and Zyprexa and many other drugs through 2012-2017 is emerging as one of the major challenges to segmental growth through 2017. The CNS sector has struggled recently, as product classes that have dominated treatment areas have come under increasing pricing pressure from generics or have been plagued with safety concerns.

The top players in the CNS market at a global level at this time are Johnson & Johnson, Pfizer, GSK, Eli Lilly, etc. Several of the top-selling CNS drugs have lost their patent protection, enabling generics to flood the market and eroding the sales figures of pharma companies.

Aruvian Research analyzes the Global CNS Market in its research offering Analyzing the Global CNS Market 2018. The report is a comprehensive analysis of the global CNS industry.

The report begins with an introduction to CNS disorders. We analyze the basic CNS disorders such as ADHD, Alzheimer's disease, epilepsy, insomnia, major depressive disorder (MDD), migraine, Parkinson's disease, and Schizophrenia.

Moving to the next section, we analyze the global CNS market through a market overview and an analysis of the market by CNS drug classes. We also analyze the industry through an industry segmentation and an analysis of the leading industry products. We look at the sales figures of the leading products in the industry.

With the rapid advances in technology, it is no wonder that there are now many novel emerging drug classes available for the treatment of CNS disorders. Some of these novel emerging drug classes for CNS disorder treatment are analyzed in our report.

Competition in the industry is analyzed in the report, following which we move on to the analysis of the major players in the global CNS industry. Players in the industry are analyzed through a corporate profile, an analysis of their major business segments, their major products and services offered, and an analysis of their presence in the CNS market. We also look at their CNS R&D pipeline, along with the company strategy for future growth in the CNS industry. A SWOT analysis of the players completes the analysis of the major industry contributors.

Future perspective of the global CNS market completes this in-depth profile of the global CNS market from Aruvian Research.

Table of Contents

A. Executive Summary

B. Introduction to CNS Disorders

  • B.1. What is CNS?
  • B.2. CNS Disorders
    • B.2.1. Attention-Deficit Hyperactivity Disorder
    • B.2.2. Alzheimer's Disease
    • B.2.3. Epilepsy
    • B.2.4. Insomnia
    • B.2.5. Major Depressive Disorder (MDD)
    • B.2.6. Migraine
    • B.2.7. Parkinson's Disease
    • B.2.8. Schizophrenia

C. Global CNS Market

  • C.1. Market Overview
  • C.2. Top CNS Products
  • C.3. Impact of Patent Expirations
  • C.4. CNS Drugs Pipeline
  • C.5. Industry R&D

D. Factors Impacting the Market

  • D.1. Growth Drivers
  • D.2. Challenges Facing the Market

E. Performance of Various Drug Classes

  • E.1. Overview
  • E.2. Antidepressants
    • E.2.1. Cymbalta (duloxetine)
    • E.2.2. Effexor (venlafaxine)
    • E.2.3. Lexapro (escitalopram)
  • E.3. Anti-epileptics
    • E.3.1. Lamictal (lamotrigine)
    • E.3.2. Lyrica (pregabalin)
    • E.3.3. Keppra/Keppra XR (levetiracetam)
  • E.4. Anti-Alzheimer's Disease Drugs
    • E.4.1. Aricept (donepezil)
    • E.4.2. Exelon (rivastigmine)
    • E.4.3. Namenda (memantine)
  • E.5. Anti-Migraine Drugs
    • E.5.1. Maxalt (rizatriptan)
    • E.5.2. Imigran/Imitrex (sumatriptan)
    • E.5.3. Zomig (zolmitriptan)
  • E.6. Antipsychotics
    • E.6.1. Abilify (aripiprazole)
    • E.6.2. Risperdal (risperidone)
    • E.6.3. Seroquel (quetiapine)
    • E.6.4. Zyprexa (olanzapine)
  • E.7. Anti-Parkinson's Disease Drugs
    • E.7.1. Comtan/Stalevo (carbidopa/levodopa/entacapone)
    • E.7.2. Mirapex/Sifrol (pramipexole)
    • E.7.3. Requip (ropinirole)
  • E.8. Hypnotics & Sedatives
    • E.8.1. Ambien/Stilnox (zolpidem)
    • E.8.2. Lunesta (eszopiclone)
  • E.9. Psychostimulants
    • E.9.1. Adderall/Adderall XR (amphetamine/dexamfetamine)
    • E.9.2. Concerta (methylphenidate)
    • E.9.3. Provigil (modafinil)
    • E.9.4. Vyvanse (lisdexamfetamine)

F. Upcoming/Recently Developed CNS Drugs

  • F.1. Overview
  • F.2. Bapineuzumab
  • F.3. Botox (onabotulinumtoxin-A)
  • F.4. IPX066
  • F.5. Levadex
  • F.6. LY2216684/NERI
  • F.7. MK-4305
  • F.8. Potiga/Trobalt
  • F.9. RG1678/RO4917838
  • F.10. Silenor
  • F.11. Solanezumab
  • F.12. Stedesa
  • F.13. TC-5214(S-mecamylamine)
  • F.14. Telcagepant
  • F.15. Valdoxan/Thymanax

G. Global CNS Drugs Market Forecast

H. Competition in the Industry

I. Leading Industry Contributors

  • I.1. AstraZeneca
    • I.1.1. Corporate Profile
    • I.1.2. Business Segment Analysis
    • I.1.3. Presence in the CNS Market
    • I.1.4. Seroquel
    • I.1.5. Zomig
    • I.1.6. Research & Development
    • I.1.7. Company Strategy in the Global CNS Market
    • I.1.8. SWOT Analysis
  • I.2. Eli Lilly
    • I.2.1. Corporate Profile
    • I.2.2. Business Segment Analysis
    • I.2.3. Presence in the CNS Market
    • I.2.4. Zyprexa
    • I.2.5. Cymbalta
    • I.2.6. Strattera
    • I.2.7. Research & Development
    • I.2.8. Company Strategy in the Global CNS Market
    • I.2.9. SWOT Analysis
  • I.3. GlaxoSmithKline
    • I.3.1. Corporate Profile
    • I.3.2. Business Segment Analysis
    • I.3.3. Presence in the CNS Market
    • I.3.4. Lamictal
    • I.3.5. Requip
    • I.3.6. Seroxat/Paxil
    • I.3.7. Research & Development
    • I.3.8. Company Strategy in the Global CNS Market
    • I.3.9. SWOT Analysis
  • I.4. Johnson & Johnson
    • I.4.1. Corporate Profile
    • I.4.2. Business Segment Analysis
    • I.4.3. Presence in the CNS Market
    • I.4.4. Concerta
    • I.4.5. Razadyne/Reminyl
    • I.4.6. Risperdal Consta
    • I.4.7. Risperdal
    • I.4.8. Topamax
    • I.4.9. Research & Development
    • I.4.10. Company Strategy in the Global CNS Market
    • I.4.11. SWOT Analysis
  • I.5. Pfizer
    • I.5.1. Corporate Profile
    • I.5.2. Business Segment Analysis
    • I.5.3. Presence in the CNS Market
    • I.5.4. Lyrica
    • I.5.5. Effexor
    • I.5.6. Zeldox/Geodon
    • I.5.7. Research & Development
    • I.5.8. Company Strategy in the Global CNS Market
    • I.5.9. SWOT Analysis

J. Glossary of Terms

K. Research Methodology

List of Figures

  • Figure 1: Stages of Alzheimer's Disease
  • Figure 2: Treatment Processes for Migraine
  • Figure 3: Symptoms of Schizophrenia
  • Figure 4: Treatment Types for Schizophrenia
  • Figure 5: Upcoming/Recently Launched CNS Drugs

List of Tables

  • Table 1: Epidemiology of ADHD in Adults, 2017
  • Table 2: Epidemiology of ADHD in Children, 2017
  • Table 3: Epidemiology of ADHD in Adults, 2017-2023
  • Table 4: Epidemiology of ADHD in Children, 2017-2023
  • Table 5: Prevalence of Alzheimer's Disease in Select Countries, 2017
  • Table 6: Epidemiology of Alzheimer's Disease, 2017-2023
  • Table 7: Prevalence of Epilepsy in Select Countries, 2017
  • Table 8: Epidemiology of Epilepsy, 2017-2023
  • Table 9: Prevalence of Insomnia in Select Countries, 2017
  • Table 10: Epidemiology of Insomnia, 2017-2023
  • Table 11: Prevalence of Major Depressive Disorders in Select Countries, 2017
  • Table 12: Epidemiology of Major Depressive Disorders, 2017-2023
  • Table 13: Prevalence of Migraine in Select Countries, 2017
  • Table 14: Epidemiology of Migraine, 2017-2023
  • Table 15: Prevalence of Parkinson's Disease in Select Countries, 2017
  • Table 16: Epidemiology of Parkinson's Disease, 2017-2023
  • Table 17: Prevalence of Schizophrenia in Select Countries, 2017
  • Table 18: Epidemiology of Schizophrenia, 2017-2023
  • Table 19: Performance of the CNS Market by Region (2012-2017)
  • Table 20: Top 10 CNS Products in 2017
  • Table 21: Patent Expiries of Key CNS Drugs/Brands
  • Table 22: Global CNS Pipeline
  • Table 23: Performance of Various CNS Drug Classes, 2017
  • Table 24: Sales of Top Antidepressant Products in 2017
  • Table 25: Sales of Top Anti-epileptics Products in 2017
  • Table 26: Sales of Top Anti-Alzheimer's Disease Products in 2017
  • Table 27: Sales of Top Anti-Migraine Products in 2017
  • Table 28: Sales of Top Antipsychotic Products in 2017
  • Table 29: Sales of Top Anti-Parkinson's Disease Products in 2017
  • Table 30: Sales of Top Hypnotics & Sedatives in 2017
  • Table 31: Sales of Top Psychostimulant Products in 2017
  • Table 32: Levadex Clinical Trial Data
  • Table 33: Sales Forecast of Leading CNS Drug Classes (in USD Million), 2017-2023
  • Table 34: Sales Forecast for Leading CNS Brands (in USD Million), 2017-2023
  • Table 35: Top Players in the CNS Market in 2017
Back to Top